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Abstract Synthetic biology is the attempt to apply the
concepts of engineering to biological systems with the aim
to create organisms with new emergent properties. These
organisms might have desirable novel biosynthetic capabil-
ities, act as biosensors or help us to understand the
intricacies of living systems. This approach has the
potential to assist the discovery and production of pharma-
ceutical compounds at various stages. New sources of
bioactive compounds can be created in the form of
genetically encoded small molecule libraries. The recombi-
nation of individual parts has been employed to design
proteins that act as biosensors, which could be used to
identify and quantify molecules of interest. New biosyn-
thetic pathways may be designed by stitching together
enzymes with desired activities, and genetic code expansion
can be used to introduce new functionalities into peptides
and proteins to increase their chemical scope and biological
stability. This review aims to give an insight into recently
developed individual components and modules that might
serve as parts in a synthetic biology approach to pharma-
ceutical biotechnology.
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Introduction
Nature provides a reservoir of active compounds that help us
to fight and cure disease (Fig. 1). We have learned to exploit
this reservoir by identifying and isolating the active
compounds, by developing strategies for their chemical
synthesis and by improving their biological activity. How-
ever, this process is laborious and very expensive. The large-
scale isolation of drugs is often hindered by the low amount
of material produced by the natural source, and the
complexity of the molecules makes their total chemical
synthesis costly to unprofitable. Transferring the ability to
biosynthesize these compounds from the source organisms to
genetically friendlier hosts would greatly facilitate their
production. Genome sequencing efforts now provide the
genetic information of entire metabolic pathways necessary
to recombinantly produce pharmaceutically relevant mole-
cules. However, biosynthetic pathways are often highly
intertwined, regulated by extensive feedback mechanisms
and require the correct organization of the individual entities
in space and time. The simple transfer of genetic information
from one organism to another is therefore rarely sufficient to
confer the biosynthetic capability. Thus, we need to under-
stand the properties of individual components as well as the
properties of entire systems and eventually learn to recombine
artificial biosynthetic networks in new hosts in a predictable,
efficient manner.The designoflifewithnovel propertiesfrom
individual modules in a way resembling the creation of new
machines in modern engineering is the ultimate aim of the
emergent discipline of synthetic biology.
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DOI 10.1007/s00253-010-2578-3In its most stringent definition, synthetic biology is
the application of the principles of engineering to the
construction of life with desired properties in a rational
and systematic way (Serrano 2007). Synthetic biology
therefore uses well-characterized, modular parts that can
be put together to create new functionality in a directed,
predictable manner (Kiel et al. 2010;N i n f a2010;T o p p
and Gallivan 2010). Several recent advances in DNA
technology encourage the followers of this new discipline:
First, inexpensive DNA synthesis enables the facile
production of codon-usage optimized genes and other
genetic elements, such as promoters and regulatory
sequences. This technology has recently been improved
towards the synthesis of an entire genome, which was
subsequently used to substitute the genome of a living cell
(Gibson et al. 2009;G i b s o ne ta l .2008a, b;L a r t i g u ee ta l .
2007, 2009). Second, rapid, next-generation DNA se-
quencing technologies provide vast amounts of genetic
information. Entire genome sequences of many organisms
are now publicly available and can be mined electronically
for relevant genes (Benson et al. 2009). Third, well-
characterized genetic modules are being developed, which
can be combined rationally to create a new function (Lu et al.
2009). The Registry of Standard Biological Parts (http://parts.
mit.edu) is a continuously growing collection of standardized
parts (“BioBricks”)t h a ta r eb e i n gu s e dt or a t i o n a l l y
create organisms with desired properties (Voigt 2006).
Directed evolution has become a widespread strategy to
adapt existing parts to novel functions. For example, the
directed evolution of tRNAs and amino acyl-tRNA
synthetases (aaRS) to decode novel, unnatural amino
acids has been used to expand the genetic code of several
organisms (Chin et al. 2003; Liu et al. 2007;W a n ge ta l .
2001) and allows genetically programming the incorpora-
tion of unprecedented functionality into proteins in vivo
(Xie and Schultz 2006).
With increasing experience in the reprogramming of
microorganisms, entirely new types of therapy might
become feasible in the future. Bacteria might no longer be
limited to the mere production of drugs but will also be able
to deliver them to the site of action. In this review, we want
to give an overview of recently developed individual
components and of the attempts to recombine them for
the production of modules of biotechnological and phar-
maceutical interest. We are trying to give an impression of
how these individual modules might eventually be used as
parts in a synthetic biology approach to pharmaceutical
biotechnology.
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Fig. 1 Molecular structure of
members of important natural
drug families. a Vancomycin, a
cyclo-peptide antibiotic.
b Cyclosporin, a family member
of the cyclic peptides and an
important immunosuppressant.
c Inhibitor of HIV budding
selected from an in vitro cyclic
peptide library (Tavassoli et al.
2008). d Artemisinin, a terpe-
noid with anti-malarial activity.
e Epothilone D, member of the
polyketide family of natural
products with cytostatic activity
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Combinatorial small molecule libraries are an efficient way
to search for new lead structures. Establishing these
libraries synthetically, however, is costly and many initial
hits unfortunately fail in subsequent rounds of screening or
in clinical trials.
Producing compound libraries directly in vivo would
have several advantages. First, maintaining and amplifying
such a library is simple and can be done by cultivating
cells. Second, the screening process is facilitated because
the genetic information remains directly coupled to the
compound. Hence, the selected compound can be identified
by analysing the genetic information of the corresponding
cell. Third, an intracellular genetic selection can directly
assay for effects on enzymatic activity, bypassing inherent
limitations of in vitro assays. Fourth, the selection is
performed in the context of a living cell requiring an
enhanced level of selectivity of the drug for its target.
Finally, potential problems with solubility and uptake of the
compound are circumvented.
Cyclic peptide libraries
Many important natural compounds are modified cyclic
peptides, for example, antibiotics like vancomycin
(Fig. 1a), the immunosuppressant drug cyclosporin
(Fig. 1b) and fungal toxins phalloidin or actinomycin D
(Katsara et al. 2006). Cyclization renders peptides resistant
to cellular degradation and restricts conformational free-
dom, potentially improving binding affinity and specificity.
Using a split intein approach, the Benkovic lab has
developed a method to produce libraries of cyclic peptides
in Escherichia coli (Scott et al. 1999). A number of
promising candidates have since been identified in libraries
generated this way (Horswill et al. 2004; Tavassoli and
Benkovic 2005; Tavassoli et al. 2008). Natural cyclic
peptides contain many modified, non-coding amino acids.
This increases the diversity of these compounds and is
crucial for their biological activity. As detailed below, the
artificial expansion of the genetic code allows the co-
translational incorporation of unnatural amino acids (Wang
et al. 2001; Xie and Schultz 2006). Combining the
Benkovic approach to the production of cyclic peptides
with the incorporation of unnatural amino acids would
vastly increase the diversity of cyclic peptides that can be
produced in vivo.
Polyketide synthases—natural synthetic biology
Another important class of natural products are the
polyketides. Polyketides are synthesized by large multi-
enzyme complexes, the polyketide synthases. These “as-
sembly lines” are built from modular components that
catalyze the formation of the carbon chain of the final
product in a stepwise manner (Fig. 2). The modular
composition of polyketide synthases makes them an ideal
playground for synthetic biologists. Their individual mod-
ules can be split and recombined to form active hybrid
enzymes (Watanabe et al. 2003b). The combinatorial
recombination of individual modules has been achieved,
and the new enzymes were shown to successfully catalyze
the formation of polyketides in E. coli (Menzella et al.
2005). This approach can potentially be used to produce
libraries of polyketides with novel biological activities in
vivo. Presently, simple recombination of different modules
often produces inactive synthases because the transfer of
intermediates between modules might be blocked or the
connectivity between modules disturbed. Growing infor-
mation on the structure of individual modules and their
connectivity (Alekseyev et al. 2007; Keatinge-Clay and
Stroud 2006; Tang et al. 2006) together with increasing
experimental experience will help to develop predictive
algorithms to rationally design synthases for “unnatural”
polyketides in a combinatorial biosynthetical approach
(Khosla et al. 2009). If a system to produce large libraries
of hybrid enzymes is connected to a selectable output (Yin
et al. 2007), active clones can be identified, even if their
frequency in the library is very low (Menzella and Reeves
2007). A combination of computer-assisted prediction,
combinatorial library design guided by structural informa-
tion and selection might eventually develop into the
mainstream of drug discovery.
De novo creation of metabolic pathways
The de novo design of biosynthetic pathways to expand the
biosynthetic potential of microorganisms is an intriguing
route towards compounds for which natural pathways have
not been elucidated or which are not of natural origin
(Prather and Martin 2008). A “retro-biosynthetic” ap-
proach, analogous to retrosynthesis in organic chemistry,
uses enzymes with evolved substrate specificity to create
artificial biosynthetic pathways de novo. Many natural
enzymes show high selectivity for their substrates, which is
the result of divergent evolution from promiscuous precur-
sor proteins (O'Brien and Herschlag 1999). However, there
are examples of natural enzymes with broad substrate
specificity. Starting from such a promiscuous enzyme, the
sesquiterpene synthase γ-humulene synthase, Keasling and
co-workers were able to recapitulate this evolutionary
process and create seven specific and active enzymes that
use different reaction pathways and produce different
products (Yoshikuni et al. 2006). These enzymes could be
used in the future to design biosynthetic pathways for
unnatural terpenoids.
Appl Microbiol Biotechnol (2010) 87:75–86 77Similarly, prenylation is an important modification
occurring on natural products, like naphterpin, conferring
anti-cancer, anti-viral or anti-microbial activity to the
molecules (Botta et al. 2005). Prenyltransferases, the
enzymes responsible for the derivatization, have been
identified and characterized (Kuzuyama et al. 2005). These
enzymes have a broad substrate spectrum and might form a
starting point for the evolution of enzymes for regio-
specific prenylation of aromatic small molecules. Engi-
neered enzymes might eventually allow us to create
enzymatic pathways de novo and to produce small
molecule libraries of differently modified compounds of
the same scaffold structure (Dietrich et al. 2009; Yoshikuni
et al. 2006).
Expanding the chemistry of life
The cellular environment imposes a constraint to the chemical
scope of reactions that can be used to create in vivo compound
libraries. Manyreactions familiar to synthetic organic chemists
require elevated temperature or are incompatible with aqueous
environments. This limitation may be overcome in the future
by the computer-assisted, directed evolution of enzymes
(Kaplan and DeGrado 2004) that catalyze unnatural chemical
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Fig. 2 Microbial polyketide
synthases are modular assembly
lines that fit polyketides together
from monomeric building
blocks. In the first step of the
reaction, the starter module is
acylated with the first unit
(1). This unit is subsequently
transferred to the first of a row
of extender modules that cata-
lyze the elongation of the poly-
ketide. All extender modules
contain at least a ketosynthase
(KS), an acyl transferase (AT)
and an acyl carrier protein
(ACP) domain. In each step, the
KS receives the acyl group unit
from the ACP of the preceding
module and the AT adds an
appropriate extender unit from
its CoA ester to the prosthetic
group of the ACP (2). The KS
then catalyzes a decarboxylative
Claisen condensation between
the acylated KS and the extend-
er unit to give a β-keto-acylated
acyl carrier protein (3). Other
modules may be included to
further modify the growing pol-
yketide chain. Upon completion
of the elongation process, the
polyketide chain is cleaved from
the polyketide synthase by the
thioesterase (TE) of the termi-
nation module (4)
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workers (Rothlisberger et al. 2008) employed computer-aided
design to engineer enzymes able to catalyze a Kemp
elimination reaction for which no natural enzyme is yet
known. It is thus conceivable that the limits to the chemistries
available in vivo will be shifted in the future, thereby
expanding the chemical scope of in vivo compound libraries.
The diversity in the chemical nature of proteins and
peptides has been tremendously increased by the invention
of strategies to introduce unnatural amino acids in vivo.
Peter Schultz and his co-workers have artificially expanded
the genetic code of several organisms (Chin et al. 2003; Liu
et al. 2007; Wang et al. 2001) and succeeded in incorpo-
rating a wide range of unnatural amino acids (Xie and
Schultz 2006). The basic principle of genetic code
expansion is the expression of an additional pair of tRNA
and its cognate aaRS in the host system (Fig. 3). Both,
tRNA and aaRS, must not be substrates for the host aaRSs
and tRNAs to ensure correct translation of host proteins.
Under these prerequisites, the tRNA can be mutated to
decode amber stop codons, for example, and the aaRS can
be evolved to specifically recognize unnatural amino acids.
This system allows the incorporation of additional, unnat-
ural amino acids in response to amber stop codons. In the
past decade, the list of unnatural amino acids that can be
incorporated in this way has grown continuously (Neumann
et al. 2008; Nguyen et al. 2009b; Xie and Schultz 2006).
Recent developments of amber and quadruplet suppressor
ribosomes now allow the efficient incorporation of multiple
different unnatural amino acids into the same protein
(Neumann et al. 2010; Wang et al. 2007). These unnatural
amino acids have side chains with unusual chemical
properties and reactivities and could be used to increase
the chemical diversity of peptides and proteins.
Drug screening
The quality of an assay system has an enormous impact on
the outcome of a screen. In order to fully profit from the
advantages of in vivo compound libraries, it is necessary to
develop intracellular assays, like a colour signal or a
genetically selectable phenotype, to detect or select positive
clones. The continuously increasing number of biosensors
could serve as such detector modules.
The Benkovic group has developed a method for
identifying small molecule inhibitors of protein–protein
interactions by combining a reverse two-hybrid system with
the split intein-mediated formation of cyclic peptide
libraries (Horswill et al. 2004). Using this system, cyclic
peptides were identified that modulate the interaction
between the two subunits of ribonucleotide reductase
(Horswill et al. 2004), HIV-Gag and TSG101 (Fig. 1c)
(Tavassoli et al. 2008) and AICAR transformylase homo-
dimerization (Tavassoli and Benkovic 2005). A similar
system that combines in vivo cyclic peptide libraries with a
Fig. 3 The principle of genetic code expansion. The basic
principle of genetic code expansion is the heterologous expression
of an additional tRNA/aminoacyl-tRNA synthetase (aaRS) pair in
the host cell. This pair is orthogonal to the host’s translational
machinery, meaning that the tRNA is not a substrate for
endogenous synthetases and that the aaRS does not charge host
tRNAs. The orthogonal tRNA is mutated to decode amber stop
codons and the orthogonal aaRS is evolved to specifically
recognize an unnatural amino acid (UAA) supplied with the growth
medium. Cells with such an expanded genetic code are able to
produce proteins with the UAA incorporated at a position encoded
by an amber codon in the mRNA
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and used to identify antibacterial cyclic peptide inhibitors of
ClpXP protease (Cheng et al. 2007).
Tsien and co-workers created the Ca
2+-sensor “Cameleon”
( M i y a w a k ie ta l .1997) by fusing calmodulin to a calmodulin-
binding peptide and flanking the construct with two fluorescent
proteins with overlapping spectral properties. Ca
2+-dependent
binding of calmodulin to its own peptide results in a
predictable conformational rearrangement that leads to a
change in energy transfer between the two fluorescent proteins.
Biosensors of this sort are being used extensive l yt om o n i t o r
the intracellular concentration and dynamics of ions and small
molecules and the activation state of signalling proteins (Balla
2009). Similar sensors could be designed for metabolites of
interest and combined with systems to produce small molecule
libraries in vivo in order to identify strains and conditions that
allow production of pharmacologically relevant compounds.
Optimization of engineered metabolic pathways depends
on our ability to measure the production of intermediates
efficiently. Mass spectrometry can be used to quantify the
relevant metabolites, but faster real-time assays allow the
identification of optimal growth condition or the screening of
mutant libraries in high-throughput formats. Mevalonate, for
example, is an important precursor in the biosynthesis of
isoprenoids. Keasling and co-workers (Pfleger et al. 2007)
engineered an auxotrophic strain of E. coli into a mevalonate
biosensor by expressing GFP. The strain reports on the
mevalonate concentration in the growth medium through a
change in growth rate. This biosensor strain can now be used
to measure mevalonate in high-throughput formats.
In a more direct approach, reporter proteins could be
created by redesigning the affinities of binding proteins, like
maltosebindingprotein(MBP),forligandsofinterest.MBPis
a member of the periplasmic binding protein superfamily that
mediates chemosensory processes in a wide range of bacteria.
This protein family has evolved to bind a variety of ligands,
suchasaminoacids,carbohydratesandions,naturallyandhas
served as starting point for the directed evolution of
biosensors, receptors and enzymes (Dwyer and Hellinga
2004). Upon ligand binding, these proteins undergo a
significant conformational change (induced fit), which has
been exploited to monitor the event by positioning environ-
mentally sensitive fluorophores within the binding site
(endosteric placement), at the rim of the binding site
(peristeric placement) or in a crevice that opens and closes
with ligand binding (allosteric placement) (de Lorimier et al.
2002). Alternatively, GFP variants have been conjugated to
the N- and C-termini of periplasmic-binding proteins in order
to monitor ligand binding by fluorescence energy transfer
(Fehr et al. 2002;F e h re ta l .2003;S c h u l t za n dM o i n i2003).
Computational design has been successfully employed to
create biosensor proteins with novel affinities for small
molecules, such as trinitrotoluene, L-lactate and serotonin
(Looger et al. 2003). These engineered sensors were
incorporated into synthetic bacterial signal transduction
pathways to regulate gene expression in response to
extracellular stimuli (Looger et al. 2003).
G-protein coupled receptors (GPCRs) are the target of the
majority of pharmaceuticals. This membrane protein family is
stimulated by extracellular ligands and initiates a signalling
cascade on the cytosolic side of the membrane upon agonist
binding. The study of GPCRs in their natural environment is
usually complicated by the presence of multiple different
receptors on a single cell combined with the tremendous
efforts necessary for its genetic manipulation. Pausch and
colleagues transplanted a mammalian GPCR into an engi-
neered Saccharomyces cerevisiae strain and connected it to a
downstream cascade controlling the expression of the his3
gene (Price et al. 1995). Activation of the receptor permitted
the cells to grow in the absence of histidine. This approach
has since been used extensively to study GPCR function and
to identify ligands and antagonists (Brown et al. 2000;M i n i c
et al. 2005; Sachpatzidis et al. 2003).
These examples demonstrate that it is possible to create
modules for the detection of a molecule of interest by rational
design. A synthetic biology approach to the production of
pharmaceuticals should employ these sensors to control the
expression level of individual parts or connect them to a
selectable output. In a case study, Farmer and Liao coupled the
E. coli Ntr regulon, which senses the intracellular metabolite
acetylphosphate, to the expression of key enzymes in the
pathway for the recombinant biosynthesis of lycopene
(Farmer and Liao 2000). This approach significantly enhanced
lycopene production and simultaneously reduced the toxic side
effects caused by metabolic imbalance. Riboswitches, RNA
elements with the ability to control the translation of a coupled
open reading frame upon binding specifically to certain
ligands, are another class of parts that can be used to control
metabolism (Famulok et al. 2007). Even before their discovery
in nature, artificial riboswitches had been designed to control
the expression of reporter genes in response to the binding of
small molecules, such as Hoechst dyes or tetracycline (Hanson
et al. 2003;S u e s se ta l .2004; Suess et al. 2003;W e r s t u c ka n d
Green 1998). These elements could be used to couple gene
expression on the translational level to the metabolic state of
the cell. Similar strategies might form the basis of high-
throughput screening systems to identify engineered strains
that are able to biosynthesize the molecule of interest.
Biosynthesis of pharmaceuticals
Recombinant DNA technology has been used for more than
three decades to engineer bacteria with the ability to
produce pharmacologically important molecules like insulin
(Goeddel et al. 1979). Progress has been made in recent
80 Appl Microbiol Biotechnol (2010) 87:75–86years towards the heterologous production of important
natural products, like terpenoids, polyketides, non-
ribosomal peptides and alkaloids. Synthetic biology
approaches are being employed to fine-tune the levels and
activities of individual steps and components. Here, we
present examples of recent successes of this strategy.
Terpenoids
Terpenoidsarealargeanddiverseclassofnaturalproductswith
important applications in human health. Well-known examples
are the anti-malarial drug artemisinin (Fig. 1d)( T a ne ta l .
1999), the anti-cancer agent paclitaxel (taxol) (Jennewein and
Croteau 2001) and eleutherobin (Long et al. 1998). A major
step forward towards the recombinant production of terpe-
noids in E. coli was the creation of a platform strain that
heterologously expressed the mevalonate pathway of S.
cerevisiae (Martin et al. 2003). The metabolic precursors
produced by this strain can be further converted into relevant
terpenoids by co-expression of the corresponding terpene
synthases and modifying enzymes. Buildingonthiswork,the
Keasling lab has engineered E. coli to produce artemisinic
acid, which can be converted chemically into artemisinin
(Roth and Acton 1989), with yields of more than
300 mg/l (Chang et al. 2007; Kizer et al. 2008;N e w m a ne ta l .
2006). Similarly, the same group has recently reprogrammed the
metabolism of S. cerevisiae to produce artemisinic acid with
titres exceeding 100 mg/l (Ro et al. 2006).
Taxol (paclitaxel) is a well-established anti-neoplastic
drug active against a variety of different cancers (Goldspiel
1997). Although the total synthesis of Taxol has been
achieved (Kingston et al. 2002), the approach is too
expensive for it being commercially practical (Borman
1994). The drug is produced by yew (Taxus) species in
about 19 individual enzymatic steps from the isoprenoid
precursor geranylgeranyl diphosphate (Jennewein and
Croteau 2001; Walker and Croteau 2001). Several Taxol
biosynthetic genes have been expressed functionally in S.
cerevisiae and used to establish the five-step biosynthesis of
an intermediate of Taxol (Dejong et al. 2006; Engels et al.
2008). Efforts are also being undertaken to establish Taxol
biosynthesis in E. coli (Huang et al. 2001). However, there
are still a number of problems to overcome, like the lack of
a complete list of enzymes involved in the production of
many important terpenoids, in order to achieve their
heterologous total biosynthesis. Still, the achievements are
promising and there is hope for cost-efficient production of
some very important natural products in the near future.
Polyketides
Polyketides are a large class of important natural products, e.g.
erythromycin, epothilone (Fig. 1e) and FK-506. They are
produced by microorganisms, most prominently actinomy-
cetes, soil-dwelling bacteria. A significant achievement in the
recombinant production of polyketides in E. coli (that
naturally does not produce any) was the engineering of the
pathway that encodes the production of 6-deoxyerythronolide
B( 6 d E B )( P f e i f e re ta l .2001). This strain was created by
optimizing precursor production, enzyme engineering and
destroying catabolic pathways. Subsequent optimization of the
strain has improved the level of 6dEB production to levels
obtained from optimized S. coelicolor strains (Pfeifer et al.
2002). Building on this work, heterologous production of
several other important polyketides or their precursors has
been achieved recently, namely, the anti-cancer drugs epothi-
lone C and D (Mutka et al. 2006) and ansamycin precursors
(Rude and Khosla 2006; Watanabe et al. 2003a), aklanoic acid
(precursor to several antitumor polyketides, e.g. doxorubicin
and aclacinomycin A) (Lee et al. 2005) and aromatic bacterial
polyketides (Zhang et al. 2008).
Metabolic fine-tuning
These promising examples illustrate the potential of a
synthetic biology approach to the recombinant production
of pharmaceutics. There are, however, significant chal-
lenges ahead. In many cases, the relevant precursor
metabolites are inefficiently produced by the host or
bottlenecks are formed during the synthesis of the product
when an intermediate is unstable or an enzyme of low
activity in the foreign environment. Synthetic biology has
the aim to create autonomous circuits for the production of
key metabolites allowing the modular combination of part
reactions into new pathways. The carefully adjusted
expression level of individual components of the pathway
is important to optimize flux and to avoid the accumulation
of toxic intermediates. Synthetic promoter libraries and a
range of engineered constitutive promoters of varying
strengths have been created (Alper et al. 2005; Hammer
et al. 2006) and could be used to fine-tune the expression
levels of all enzymes in a pathway in order to optimize
metabolic flux.
The Church lab has recently published a novel technology
for multiplex automated genome engineering (“MAGE”)t o
optimize metabolic pathwaysinE. coli. By feeding cells with
synthetic oligonucleotides, which are probably used as
Okazaki fragments during replication, the authors were able
to mutate and fine-tune ribosomal binding sites genome-wide
(Wang et al. 2009). They have used this method to increase
the production of lycopene in an engineered E. coli strain by
a factor of five within only 3 days of evolution. The same
approach might allow optimizing the production of other
metabolites if a simple screening assay is available. The use
of an automated setup greatly accelerated and increased the
throughput of this technology. The development of similar
Appl Microbiol Biotechnol (2010) 87:75–86 81automated systems will have a major impact on the de novo
creation of biosynthetic pathways and regulatory networks in
the future.
An important reoccurring theme of cellular metabolism
is compartmentalization and channelling of metabolites
(Ovadi and Srere 2000). This avoids side reactions
(especially hydrolysis) of activated intermediates and
prevents toxic side effects. A strategy that mimics this
organization of enzymes would facilitate the design of
efficient metabolic pathways. A first step towards this aim
has recently been taken: By fusing the components of the
metabolic pathway for mevalonate to peptide motifs,
Keasling and co-workers (Dueber et al. 2009) were able
to recruit them into synthetic protein scaffolds and to
optimize their stoichiometry within the synthetic complex.
The activity of the pathway was thereby increased by a
factor of 77. Compartmentalization (for example, in
protein-based organelles that exist in many bacteria (Yeates
et al. 2008)) can also help to establish new chemical
reactions by shielding unstable intermediates from a hostile
environment or by creating a special phase, e.g. with low or
high pH or hydrophobicity.
Bacteria as drug delivery units
In recent years, we have witnessed an explosion of new
technologies to manipulate cellular genetic information.
Our engineering abilities allow us to design cells with
artificial genomes (Gibson et al. 2009; Gibson et al. 2008a,
b; Lartigue et al. 2007, 2009), promising the advent of
customized drug-producing or therapeutic bacteria. It might
become possible to equip “synthetic” organisms with just
the genetic information necessary for function, while
omitting any interfering and potentially dangerous genetic
and metabolic material. These cells could be rationally
equipped with modular genetic elements to create an
organism with a desired phenotype. In a futuristic scenario,
genetic devices might be combined to program organisms
like robots. First attempts produced newly combined
biosensor modules under newly linked genetic circuits
(Kobayashi et al. 2004; Looger et al. 2003; Lu et al. 2009;
You et al. 2004). For example, a chimeric sensor domain of
a phytochrome from cyanobacteria fused to a signal
transduction domain of E. coli was used to design an
E. coli strain responding to light (Levskaya et al. 2005).
Engineering new bacterial sensors to regulate genes in
response to a new environmental context can be extended
to create other sensors and also reprogram downstream
signalling at wish. Promoters, for example, could be built to
integrate (multiple) specific signals (Anderson et al. 2007).
This approach can be extended to design live bacteria as
targeted delivery systems for live vaccination, as probiotics
and anti-tumour agents (Garmory et al. 2003; Martin et al.
2003; Nguyen et al. 2010; Pawelek et al. 2003). Various
bacteria invade tumours and have been engineered to
destruct them by releasing a chemotherapeutic prodrug
(Nemunaitis et al. 2003), via secretion of TNFα (Dang
et al. 2001; Nuyts et al. 2001) and cytokines (Murray et al.
1996). However, a synthetic biological approach would
allow designing a bacterium rationally with desired capa-
bilities and safety requirements. The Voigt lab constructed
an E. coli strain that senses a low-oxygen microenviron-
ment such as found in tumour tissues. Hypoxia is the cue in
this particular E. coli strain to upregulate a Yersinia
pseudotuberculosis adhesin protein (invasin) sufficient for
E. coli to invade mammalian cells. Because invasion is only
efficient from a certain cell density, the Voigt lab further
equipped this E. coli with a second sensor including
another genetic circuit that senses cell density (quorum-
sensing circuit from Vibrio fischeri) (Anderson et al. 2006).
Thus, this E. coli strain should specifically invade tumour
cells in a population density-dependent manner.
The type III secretion apparatus, usually used by certain
bacteria to pump effector proteins into the eukaryotic host
cytoplasm for manipulation, was exploited in a synthetic
biology approach to pump spider silk proteins into the
medium (Widmaier et al. 2009). Combined with the previous
approaches, a (synthetic) bacterial strain equipped with
rationally linked sensors and genetic circuits might be able
to sense the environment of damaged tissues, specifically to
adhere and release therapeutic proteins into the infected cell
and thus could kill (or heal) damaged or infected tissues.
Refining such approaches together with biological “safety
tasks”, which can also be synthetic, would be a further step
towards the use of safe therapeutic bacteria.
Optimizing drugs
Often the identification of a new drug candidate is only the
beginning of a laborious and time-consuming effort to
optimize and mature its pharmacokinetic properties.
Small therapeutic proteins, for example, have a short
residence time in the bloodstream. This can be improved by
modifying surface residues with polyethylene glycol (PEG).
Random derivatization usually creates an ill-defined mix-
ture of molecules with varying degrees of PEGylation. A
strategy to introduce PEG residues in a defined way is
therefore much preferable over random modification. This
is being tried using incorporation of unnatural amino acids
with an alkyne side chain (Deiters et al. 2004). Subsequent
modification with azide group-containing PEG residues
generates proteins with site-specific PEGylation.
Many proteins are stabilized by disulfide cross-bridges.
In recombinant proteins, these disulfide bonds are usually
82 Appl Microbiol Biotechnol (2010) 87:75–86difficult to reproduce because of their redox sensitivity and
the lack of relevant chaperones. A general method for the
genetically programmed installation of directed redox-
insensitive cross-links has recently been devised (Neumann
et al. 2010). The authors combined evolved orthogonal
ribosomes with two pairs of mutually orthogonal tRNA/
aaRS pairs to incorporate two different unnatural amino
acids into the same protein. The side chains of these amino
acids contained an azide and an alkyne functional group
that formed a cross-link upon addition of a Cu(I) catalyst.
Post-translational modifications (PTMs) are often present
on proteins and can tremendously change their properties.
However, recombinant proteins from E. coli are usually
unmodified. It is therefore often necessary to use eukaryotic
expression systems to produce correctly processed proteins,
but even then the pattern of modifications is usually different
from the natural situation. Lysine acetylation has been
recognized as a widespread PTM in prokaryotes and
eukaryotes (Choudhary et al. 2009; Kim et al. 2006;Z h a n g
et al. 2009). The effect of the modification on protein
function is largely unexplored. A method to genetically
encode this PTM on recombinant proteins in E. coli has
recently been devised (Neumann et al. 2008; Neumann et al.
2009). Hence, therapeutic proteins harbouring this modifica-
tion can now be produced recombinantly without any
knowledge of the modifying enzymes involved. Similar
methods exist to produce proteins containing lysine methyl-
ation or tyrosine sulphation (Liu and Schultz 2006;N g u y e n
et al. 2009a). Other PTMs that cannot be encoded genetically
to date, like glycosylations or ubiquitination, can be
mimicked by incorporating a chemical handle into the
protein at the site of the modification followed by in vitro
derivatization (Liu et al. 2003).
Conclusion and perspective
In this review, we did not intend to give a complete list of all
the parts available to a synthetic biology approach to
pharmaceutical biotechnology and we apologize to those
whose work was left unmentioned (please see Kiel et al.
(2010), Ninfa (2010) and Topp and Gallivan (2010) for more
recent reviews of this topic.) Our aim was to give a flavour
of the potential impact that synthetic biology might have on
the pharmaceutical industry. Future work should use these
parts to create systems for the simultaneous production,
identification and optimization of new drugs. Such an
approach might look as follows: A reporter is engineered
to detect a protein–protein interaction or an enzymatic
activity of interest. To this end, one could develop biosensors
that sense a reaction product or genetic circuits that are
activated once a certain interaction is prevented. Such a
sophisticated system will reduce the number of false hits
during the screening process. This reporter system is subse-
quently combined with various in vivo compound libraries to
isolate clones with the desired activity. Newly identified lead
structures can be further improved afterwards, for example,
with the help of unnatural amino acids. Their biosynthesis
could be optimized for instance by using MAGE or by
compartmentalizing the enzymes involved. Any improvement
to the system could be identified or selected quickly by the
reporter. A lot of work need to be invested before such an
approach will become the mainstream of drug development.
An important next step towards this aim would be to form
well-characterized modular parts from individual components
that can be freely and quickly combined in the true sense of a
synthetic biology approach to pharmaceutical biotechnology.
The automation of such an approach combined with the
development of computational design tools for synthetic
biology (Marchisio and Stelling 2009)w i l lb ea ni m p o r t a n t
technological advance that will help in its realization.
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